JAC Advance Access originally published online on February 9, 2006
Journal of Antimicrobial Chemotherapy 2006 57(4):741-746; doi:10.1093/jac/dkl014
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis
1 Department of Pediatric Pulmonology and Allergology, Erasmus MC–Sophia Children's Hospital, Rotterdam, The Netherlands; 2 Department of Medical Microbiology & Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
* Corresponding author. Tel: +31-104633510; Fax: +31-104633875; E-mail: a.ott{at}erasmusmc.nl
Objectives: Azithromycin is used to modulate exuberant inflammatory response in patients with cystic fibrosis (CF). The purpose of this study was to determine the association between long-term use of azithromycin in CF patients and change over time in macrolide susceptibility of Staphylococcus aureus and Haemophilus spp.
Methods: The study was performed at the Erasmus MC–Sophia Children's Hospital. CF patients' sputum cultures were obtained at routine visits and at pulmonary exacerbations. All cultures between January 1999 and March 2004 were included. Antibiotic susceptibility of S. aureus and Haemophilus spp. was tested routinely. Susceptibility was compared with isolates from sputum of non-CF patients. Logistic regression was used to analyse the association between azithromycin use and resistance, adjusting for age, Pseudomonas carriage and time-trends.
Results: In March 2004 one-third of CF patients were on azithromycin maintenance treatment. S. aureus (715 isolates) and/or Haemophilus (537 isolates) were cultured in 141 of the 155 patients on one or more occasions. The study period was divided into octiles. Erythromycin resistance in S. aureus increased from 6.9 to 53.8% and clarithromycin resistance in Haemophilus spp. from 3.7 to 37.5%. Resistance but also isolation rates were strongly related to azithromycin use. Resistance of 3217 S. aureus control isolates remained stable and resistance of 3257 Haemophilus controls increased, although at a slower rate than CF isolates.
Conclusions: Over a 4 year period, azithromycin maintenance therapy in our CF population was associated with an increase in macrolide resistance in S. aureus and Haemophilus spp.
Keywords: clarithromycin , erythromycin , immunomodulation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Tazumi, Y. Maeda, C. E. Goldsmith, W. A. Coulter, C. Mason, B. C. Millar, M. McCalmont, J. Rendall, J. S. Elborn, M. Matsuda, et al. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF) J. Antimicrob. Chemother., September 1, 2009; 64(3): 501 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. J. Crosbie and M. A. Woodhead Long-term macrolide therapy in chronic inflammatory airway diseases Eur. Respir. J., January 1, 2009; 33(1): 171 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hodge, G. Hodge, H. Jersmann, G. Matthews, J. Ahern, M. Holmes, and P. N. Reynolds Azithromycin Improves Macrophage Phagocytic Function and Expression of Mannose Receptor in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 139 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McCormack, S. Bell, S. Senini, K. Walmsley, K. Patel, C. Wainwright, D. Serisier, M. Harris, and S. Bowler Daily versus weekly azithromycin in cystic fibrosis patients Eur. Respir. J., September 1, 2007; 30(3): 487 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Tramper-Stranders, C. K. van der Ent, S. A. M. Gerritsen, A. Fleer, J. L. L. Kimpen, and T. F. W. Wolfs Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts? J. Antimicrob. Chemother., September 1, 2007; 60(3): 665 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C Bell and P. J Robinson Exacerbations in cystic fibrosis: 2 {middle dot} Prevention Thorax, August 1, 2007; 62(8): 723 - 732. [Abstract] [Full Text] [PDF]
|
|